Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for AC Immune (ACIU) over the last 11 years, with Q3 2025 value amounting to $214.5 million.

  • AC Immune's Liabilities and Shareholders Equity fell 2390.5% to $214.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $942.7 million, marking a year-over-year increase of 3.55%. This contributed to the annual value of $263.6 million for FY2024, which is 2789.77% up from last year.
  • As of Q3 2025, AC Immune's Liabilities and Shareholders Equity stood at $214.5 million, which was down 2390.5% from $229.8 million recorded in Q2 2025.
  • AC Immune's 5-year Liabilities and Shareholders Equity high stood at $283.5 million for Q4 2021, and its period low was $221524.5 during Q3 2021.
  • Its 5-year average for Liabilities and Shareholders Equity is $188.1 million, with a median of $212.8 million in 2022.
  • As far as peak fluctuations go, AC Immune's Liabilities and Shareholders Equity crashed by 9992.05% in 2021, and later surged by 10104457.33% in 2022.
  • AC Immune's Liabilities and Shareholders Equity (Quarter) stood at $283.5 million in 2021, then crashed by 31.93% to $193.0 million in 2022, then increased by 6.78% to $206.1 million in 2023, then increased by 27.9% to $263.6 million in 2024, then decreased by 18.62% to $214.5 million in 2025.
  • Its last three reported values are $214.5 million in Q3 2025, $229.8 million for Q2 2025, and $234.8 million during Q1 2025.